Spyre Therapeutics, Inc. (SYRE) Tops Q4 EPS by 22c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q4 EPS of ($0.81), $0.22 better than the analyst estimate of ($1.03).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• loanDepot receives NYSE non-compliance notice over stock price
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises